Literature DB >> 18700063

Overactive bladder.

Lesley K Carr1.   

Abstract

Overactive bladder (OAB) is a common condition (prevalence 14%-18% of Canadians) and has a significant negative impact on quality of life. OAB may be idiopathic or may occur with other common conditions such as bladder outlet obstruction, neurological disease, or stress incontinence. Primary care physicians may safely diagnose this condition by history and physical exam with a minimum of widely available lab tests. Management with behavioral therapies and pharmacotherapy is generally quite successful and warranted. Multiple anticholinergic medications are available and have been shown to be effective. Subtle differences in structure and mechanism of these agents may yield improved therapeutic benefit or tolerability and thus it is reasonable to try more than one drug to achieve the optimal results. For patients that fail behavioral and initial pharmacotherapy or when other complicating conditions are identified, referral to a specialist is indicated; however, the majority of patients with OAB do not require cystoscopy or urodynamics. Successful treatments for OAB do exist and it is worth screening for these disabling complaints at the primary care level.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18700063

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  3 in total

Review 1.  Vulnerable elderly patients and overactive bladder syndrome.

Authors:  Stephen R Kraus; Tamara Bavendam; Tiffany Brake; Tomas L Griebling
Journal:  Drugs Aging       Date:  2010-09-01       Impact factor: 3.923

2.  The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.

Authors:  Bimal K Malhotra; Penelope H Crownover; Robert LaBadie; Paul Glue; Scott A MacDiarmid
Journal:  Eur J Clin Pharmacol       Date:  2009-11-14       Impact factor: 2.953

3.  Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.

Authors:  Linda Cardozo; Timothy Hall; John Ryan; Caty Ebel Bitoun; Imran Kausar; Amanda Darekar; Adrian Wagg
Journal:  Int Urogynecol J       Date:  2012-05-11       Impact factor: 2.894

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.